Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: HAIC+Serplulimab （HLX10）+ Bevacizumab Biosimilar（HLX04） Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials